Supernus Pharmaceuticals | SUPN - Equity Capital And Reserves


Supernus Pharmaceuticals reported $1.03B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Eisai JPY 906.56B 7.57B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Xeris Pharmaceuticals USD -9.73M 22.74M Jun/2026